RO 3201195

Drug Profile

RO 3201195

Alternative Names: RO320-1195

Latest Information Update: 04 Jul 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Roche Palo Alto
  • Class Antirheumatics; Pyrazoles; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Jul 2006 No development reported - Phase-I for Rheumatoid arthritis in USA (unspecified route)
  • 27 Sep 2001 Phase-I clinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 27 Sep 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top